CRISPR Short Sellers Retreat Before Tuesday's Print

Among gene-editing peers, CRSP carries one of the lighter short positions heading into its November 3 results. BEAM, NTLA and EDIT all gained more than 11% on the week while CRSP added only 4.1%, suggesting stock-specific drag rather than sector weakness. CRSP's short interest now stands at 16.8% of free float, down more than 21% over the past month and at its lowest level in at least a year. That unwind has come in a structured way: positions fell roughly 11% over the past week alone, a move 1.7 standard deviations below the stock's typical weekly change, which points to deliberate cover rather than a short squeeze. Borrow costs remain low at 0.53%, and availability is comfortable at 145%, well clear of the 52-week trough of 0.23% hit earlier this year. Options paint a different picture: the put/call ratio has dropped to 0.50, more than two standard deviations below its 20-day average of 0.54, its most call-heavy reading in months, and close to the 52-week low of 0.41.

The analyst community is broadly constructive but split on how much that optimism is already priced in. Nine firms rate the stock Buy or equivalent, with four at Outperform, and the recent UBS initiation at Neutral with a $52 target, essentially at the current price of $51.42, frames the tension clearly: even a bullish-leaning desk sees limited near-term upside. Targets elsewhere range from Bernstein's $56 to Piper Sandler's $110, a spread that reflects genuine disagreement about pipeline value. The bull argument centres on CTX310's one-year ANGPTL3 reduction of 78.6% at the highest dose and the company's roughly $2.1 billion in estimated year-end 2026 cash, which funds development without an immediate need for dilutive capital. Bears point to patent uncertainty around the CRISPR/Cas9 platform, dependence on partnership revenues from Vertex and Bayer, and the risk that Casgevy sales disappoint if adoption remains slow.

The most notable near-term signal comes from inside the company itself. CEO Samarth Kulkarni sold approximately $2.4 million worth of shares on October 19 in open-market transactions outside a 10b5-1 plan, following a smaller discretionary sale on October 14. Discretionary sales by a CEO in the weeks before an earnings report attract attention precisely because they are not pre-arranged. The net insider position over the past 90 days is minus $4.9 million, skewed by these open-market sales. Director George Simeon's October 14 sale was executed under a 10b5-1 plan and carries less signal. ARK Investment Management remains the largest institutional holder at 9.78% and added around 545,000 shares in the quarter to September, while BlackRock added roughly 669,000, providing a counterweight from longer-duration holders.

Tuesday's print will test whether the accelerating unwind in short positions reflects genuine improvement in the fundamental outlook for Casgevy and CTX310, or whether it simply reflects shorts locking in gains ahead of a binary catalyst, with Wikipedia attention running at a z-score of 2.25 against the stock's own recent history suggesting retail interest is picking up just as the institutional picture turns more complicated.